What moved LLY and why it matters

Eli Lilly’s latest reported catalyst is the October 29, 2026 third-quarter update: revenue rose 39% year over year to $24.4 billion, adjusted EPS came in at $7.48, and management lifted full-year 2026 revenue guidance to $91.0 billion to $92.0 billion while also raising underlying non-GAAP EPS guidance. That matters because the market is still anchoring the stock to execution in obesity and diabetes, where Mounjaro and Zepbound remain the main revenue engines. citeturn0search0

RBC Capital reiterated an Outperform rating and a $1,600 target on November 17, 2026, while Barclays raised its target to $1,550 on November 16, 2026. Stockanalysis.com, citing 31 analysts polled by S&P Global, shows a consensus Buy rating and an average target of $1,470, with a wide range from $940 to $1,700. That spread says the market is still rewarding Lilly’s growth profile, but the path higher is not being priced as a straight line. citeturn0search1turn0search2turn0search3

Technical picture: constructive pullback, not a clean breakout

At $1,356.25, LLY is trading below the 7-day SMA of $1,399.02, the 20-day SMA of $1,403.22, the 12-day EMA of $1,393.00, and the 26-day EMA of $1,374.24. That is a short-term distribution pattern, but the stock remains above the 50-day SMA of $1,306.70, which keeps the medium-term trend intact. citeturn0search4

Momentum is soft rather than broken. RSI at 46.54 is neutral, MACD histogram is flat at 0.0000, and stochastic readings are depressed, with %K at 9.54 and %D at 7.64. In plain terms, the stock has lost upside momentum, but the indicator mix does not yet confirm a full trend reversal. citeturn0search4

Price is also sitting near the lower Bollinger Band at $1,334.34, with %B at 0.1590, which signals the shares are near lower-band support rather than stretched on the upside. The key levels from the daily structure are clear: immediate resistance at $1,378.67, stronger resistance at $1,401.10, immediate support at $1,337.91, and strong support at $1,319.58. citeturn0search4

What Binance Futures is signaling

Binance perpetual futures show a neutral funding rate, which means there is no obvious crowding cost on either side. Open interest is 2,198 contracts, with a daily open interest value of $3.14 million and a 24-hour increase of 5.49%, so new positioning is being added even as price slips. citeturn0search4

The positioning mix is mildly defensive: Binance global accounts show 46.3% long versus 53.7% short, and top-trader accounts are even more skewed at 44.1% long versus 55.9% short. The taker buy/sell ratio of 1.4854, however, shows aggressive buying pressure in the latest 1-hour window. That combination usually points to a market that is trying to stabilize, but not yet in agreement on direction. citeturn0search4

Scenario lens

If LLY can reclaim the $1,378.67 to $1,401.10 resistance band, the market would be signaling that the pullback is being absorbed and that post-earnings support is still intact. If it fails to hold $1,337.91, the next test is the $1,319.58 strong support area, which also sits close to the stock’s 50-day average and would be the more important line for trend followers. citeturn0search4

The cleanest read right now is that Eli Lilly still has a strong fundamental story, but the short-term tape is consolidating around recent gains. Until price reclaims the moving-average cluster, the burden is on bulls to prove the post-earnings strength is more than a one-way move.